Personalis, Inc. (NASDAQ:PSNL) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its price target from Morgan Stanley lowered from $11 to $10. The firm’s analyst maintained an Equal Weight rating on the stock after updating its estimates to reflect an increased 2026 net loss guidance and higher projected long-term operating expenses. In another development, ...

Core Insights - Personalis, Inc. has published the PREDICT-DNA study in the Journal of Clinical Oncology, highlighting advancements in ultrasensitive molecular residual disease testing for breast cancer [1] Company Overview - Personalis, Inc. is recognized as a leader in advanced genomics specifically for precision oncology, indicating its strong position in the healthcare sector focused on cancer treatment [1] Study Findings - The PREDICT-DNA study demonstrates that ultrasensitive ctDNA assessment can effectively evaluate and detect minimal residual disease in breast cancer patients, showcasing the potential of NeXT Personal technology [1]

Core Insights - Personalis achieved significant milestones in 2025, including Medicare coverage for breast cancer and lung cancer surveillance, which enhances the legitimacy of its tests and allows for ongoing surveillance billing [1][7][5] - The company is targeting a clinical volume of 43,000 to 45,000 tests in 2026, representing approximately 170% year-over-year growth, with over 900 oncologists currently ordering the tests [2][8] - The NeXT Personal test demonstrates high sensitivity, capable of detecting one tumor DNA fragment in a million, which facilitates earlier detection of cancer recurrence compared to standard imaging [3][5] Clinical Performance - In Q4 2025, Personalis delivered 6,183 clinical tests, marking a 41% sequential increase and a 329% year-over-year increase, with over 16,000 tests delivered throughout the year [4][8] - The company is focused on scaling its ultra-sensitive NeXT Personal MRD assay, which is currently utilized by more than 900 oncologists [8][5] Financial Overview - For 2025, Personalis reported total revenue of $69.6 million, with Q4 revenue at $17.3 million, reflecting a strategic shift away from lower-value work [6][16] - The company anticipates 2026 revenue guidance of $78 million to $80 million, with a projected net loss of approximately $105 million and cash usage of about $100 million [6][24] Research and Development - Personalis is involved in over 35 studies to support the performance of NeXT Personal, with ongoing trials demonstrating its clinical utility in various cancer types [10][12] - Landmark studies, such as the TRACERx lung cancer study and the Royal Marsden breast cancer study, have shown strong sensitivity and specificity for NeXT Personal [10][11] Biopharma Collaboration - The company reported a nearly 240% growth in biopharma MRD revenue over 2024, indicating a stabilizing environment in the biopharma sector [14][15] - For 2026, biopharma revenue is expected to be between $55 million and $56 million, with MRD revenue projected at $20 million to $21 million [15][19] Market Strategy - Personalis plans to increase its dedicated field team to enhance market share, with an estimate of 20% of 2026 test volume expected from breast cancer and 15% to 20% from lung cancer [20][5] - The introduction of a new "Real-Time Variant Tracker" report aims to assist in detecting mutations during MRD surveillance, with positive early feedback from physicians [21][5]

分组1 - Personalis reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.31, representing an earnings surprise of +16.13% [1] - The company posted revenues of $17.35 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 4.66%, compared to year-ago revenues of $16.8 million [2] - Personalis has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates two times during the same period [2] 分组2 - The stock has gained approximately 4.4% since the beginning of the year, outperforming the S&P 500's gain of 1.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.25 on revenues of $18.22 million, and for the current fiscal year, it is -$0.93 on revenues of $80.03 million [7] - The Medical - Generic Drugs industry, to which Personalis belongs, is currently in the bottom 34% of the Zacks Industry Rank, indicating potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $17.3 million, a modest 3% increase year-over-year compared to $16.8 million in Q4 2024 [21] - Full year revenue for 2025 was $69.6 million, reflecting a transitional period for the top line [9][22] - Biopharma revenue was $10.9 million in Q4 2025, down from $12.2 million in Q4 2024, while full year biopharma revenue was $49 million compared to $51 million in 2024 [23] - Clinical revenue recognized was $0.9 million in Q4 2025 and $2 million for the full year, compared to $0.2 million and $0.8 million in 2024 respectively [24] - Gross margin was 11% in Q4 2025 and 22.7% for the full year, with expectations of margin dilution continuing into 2026 [25] Business Line Data and Key Metrics Changes - Clinical tests delivered in Q4 2025 totaled 6,183, representing a 41% sequential growth and a 329% increase year-over-year [8] - For the full year 2025, over 16,000 clinical tests were delivered, growing 394% over 2024 [8] - MRD biopharma revenue grew nearly 240% over 2024, indicating strong demand for the strategic MRD offering [9][18] Market Data and Key Metrics Changes - The clinical market for MRD testing is expected to mature into a $20+ billion opportunity, with Personalis well-positioned to capture a significant share [7] - The company achieved two Medicare coverage decisions for breast and lung cancer, validating the value of its technology [15] Company Strategy and Development Direction - The company is focused on scaling its Win-in-MRD strategy, with expectations to quadruple clinical volumes in 2026 [12] - Plans to expand commercial efforts include onboarding more oncologists and increasing the number of dedicated sales representatives [13] - The introduction of the Real-Time Variant Tracker report is aimed at enhancing the utility of the NeXT Personal test for clinicians [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying demand for MRD testing and the potential for significant growth in 2026, with revenue guidance set between $78 million and $80 million [12][29] - The company is navigating a planned decline in revenue from legacy contracts while building a diversified and sustainable high-growth engine [23] - Management highlighted the importance of clinical evidence and reimbursement decisions in driving future growth [16] Other Important Information - The company ended Q4 2025 with $240 million in cash and short-term investments, indicating a strong balance sheet [27] - Operating expenses for Q4 2025 were $27.2 million, up from $22.7 million in Q4 2024, primarily due to increased commercial and R&D investments [26] Q&A Session Summary Question: How does the recent reimbursement affect the focus of sales representatives? - Management indicated that reimbursement provides legitimacy in discussions with physicians and enhances the company's ability to invest in growth [33][35] Question: Are there any pushouts or cancellations in biopharma contracts? - Management noted that the sector is stabilizing and they have not seen significant pushouts or cancellations, with continued growth in MRD revenue [40][42] Question: What is the expected mix of reimbursed versus non-reimbursed tests in 2026? - Approximately 20% of tests are expected to come from breast cancer, 15-20% from lung cancer, and 20% from immunotherapy, with the remainder from other indications [48] Question: What is the strategy for evidence generation for new cancer indications? - The company is focused on working with key opinion leaders to establish strong clinical evidence for new indications, which is crucial for the Medicare coverage process [100]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $17.3 million, a modest 3% increase year-over-year compared to $16.8 million in Q4 2024 [21] - Full year revenue for 2025 was $69.6 million, reflecting a transitional period for the top line due to a shift in commercial focus [22][29] - Biopharma revenue was $10.9 million in Q4 2025, down from $12.2 million in Q4 2024, while full year biopharma revenue was $49 million compared to $51 million in 2024 [23] - Clinical revenue recognized was $0.9 million in Q4 2025, up from $0.2 million in Q4 2024, indicating growth in clinical testing [24] - Gross margin was 11% in Q4 2025 and 22.7% for the full year, with expectations of margin dilution continuing into 2026 [25] Business Line Data and Key Metrics Changes - Clinical tests delivered in Q4 2025 totaled 6,183, representing a 41% sequential growth and a 329% increase year-over-year [8] - For the full year 2025, over 16,000 clinical tests were delivered, growing 394% over 2024 [9] - MRD biopharma revenue grew nearly 240% over 2024, indicating strong demand for MRD testing services [9][18] Market Data and Key Metrics Changes - The clinical market for MRD testing is expected to mature into a $20-plus billion opportunity, with Personalis well-positioned to capture a significant share [7] - The company achieved two Medicare coverage decisions for breast and lung cancer, validating the value of its technology [15] Company Strategy and Development Direction - The company aims to scale its MRD testing services and expand its commercial footprint, with a target of 43,000-45,000 tests in 2026, representing about 170% growth year-over-year [13] - The strategic focus is on building clinical evidence and expanding reimbursement coverage, with plans to submit for coverage in additional cancer types [12][19] - The company is transitioning from a high-growth testing company to a high-margin reimbursed clinical powerhouse [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying demand for MRD offerings and the potential for significant growth in 2026, with revenue guidance set at $78 million-$80 million [12][29] - The company is focused on scaling clinical volumes and expects to see benefits from investments in market share over the next 2-3 years [25][30] Other Important Information - The company ended Q4 2025 with cash and short-term investments of $240 million and no debt, providing a strong financial position to execute its plans [27] - Operating expenses for Q4 2025 were $27.2 million, reflecting investments in commercial efforts and R&D [26] Q&A Session Summary Question: How does the recent reimbursement affect the focus of reps internally and externally? - Management indicated that reimbursement provides legitimacy in discussions with physicians and helps to reinforce the value of their offerings [35] Question: Are there any pushouts or cancellations in the biopharma contracts? - Management noted that the sector is stabilizing and they have not seen significant pushouts or cancellations [41] Question: What is the expected mix of volumes for reimbursed versus non-reimbursed indications? - Approximately 20% of tests are from breast cancer, 15%-20% from lung cancer, and 20% from immunotherapy, with a significant portion still being unreimbursed [50] Question: What is the strategy for evidence generation for additional cancer indications? - The company is focused on working with key opinion leaders to establish strong evidence for new indications, which is crucial for the Medicare coverage process [101]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $17.3 million, a modest 3% increase year-over-year compared to $16.8 million in Q4 2024 [19] - Full year revenue for 2025 was $69.6 million, reflecting a transitional period for the top line [7][20] - Biopharma revenue was $10.9 million in Q4 2025, down from $12.2 million in Q4 2024, while full year biopharma revenue was $49 million compared to $51 million in 2024 [20] - Clinical revenue recognized was $0.9 million in Q4 2025, up from $0.2 million in Q4 2024, and $2 million for the full year 2025 compared to $0.8 million in 2024 [21] - Gross margin was 11% in Q4 2025 and 22.7% for the full year, with expectations of margin dilution continuing into 2026 [22][23] Business Line Data and Key Metrics Changes - The company delivered 6,183 clinical tests in Q4 2025, representing a 41% sequential growth and a 329% increase year-over-year [6] - For the full year 2025, over 16,000 clinical tests were delivered, growing 394% over 2024 [6] - MRD biopharma revenue grew nearly 240% over 2024, indicating strong demand for the strategic MRD offering [7][20] Market Data and Key Metrics Changes - The clinical market for MRD testing is expected to mature into a $20-plus billion opportunity, with Personalis well-positioned to capture a significant share [5] - The company achieved two Medicare coverage decisions for breast and lung cancer, validating the value of its technology [12] Company Strategy and Development Direction - The company is focused on scaling its MRD strategy, with expectations to quadruple clinical volumes in 2026 [10] - The strategic roadmap includes expanding relationships with biopharma companies and increasing the number of oncologists ordering tests [11][16] - The introduction of the Real-Time Variant Tracker report is aimed at enhancing the clinical utility of the NeXT Personal test [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong underlying demand for MRD testing and the potential for significant revenue growth in 2026, with guidance of $78 million to $80 million [10][27] - The company is navigating a planned decline in revenue from legacy contracts while building a diversified and sustainable high-growth engine [20] - Management highlighted the importance of ongoing clinical evidence generation to support reimbursement initiatives and technology development [24][100] Other Important Information - The company ended Q4 2025 with cash and short-term investments of $240 million and no debt, allowing for continued investment in growth strategies [25][26] - Operating expenses for Q4 2025 were $27.2 million, up from $22.7 million in Q4 2024, primarily due to increased commercial and R&D expenses [24] Q&A Session Summary Question: How does the recent reimbursement affect the focus of reps internally and externally? - Management indicated that reimbursement provides legitimacy in discussions with physicians and key opinion leaders, enhancing the company's position in the market [30][32] Question: Are there any pushouts or cancellations of contracts in the biopharma sector? - Management noted that the sector is stabilizing, with no significant pushouts or jolts to the business, and they are making progress in MRD [36][39] Question: What is the expected mix of reimbursed versus non-reimbursed indications in 2026? - Approximately 20% of tests are expected to come from breast cancer, 15%-20% from lung cancer, and 20% from immuno-oncology, with the remainder from other indications [46] Question: What are the expectations for adjuvant reimbursement in breast and lung cancer? - Management is focused on driving hard to submit for coverage for neoadjuvant breast cancer and colorectal cancer this year, but exact timelines are dependent on publication acceptance [95]

Revenue Performance - Total revenue for 2025 was $69.6 million, a decrease of 18% or $15.0 million compared to 2024, primarily due to lower revenue from Enterprise sales, which dropped to $5.9 million from $25.4 million[344]. - Revenue from population sequencing increased by $4.3 million, or 58%, contributing positively to overall revenue despite the decline in Enterprise sales[344]. - Clinical test revenue reached $2.0 million, more than double the $0.8 million reported in 2024, indicating strong clinical momentum[346]. - Clinical test volume increased to 16,233 tests, a nearly 400% rise from 3,285 tests in 2024, reflecting significant growth in testing services[346]. - Total revenue for 2025 was $69.648 million, a decrease of 18% from $84.614 million in 2024[364]. - Revenue from pharma testing services decreased by 4% to $48.661 million, primarily due to a reduction in clinical trial samples processed for Moderna[364]. - Enterprise sales revenue dropped significantly by 77% to $5.885 million, attributed to the expiration of minimum volume commitments with Natera[366]. - Population sequencing revenue increased by 58% to $11.766 million, driven by a higher number of samples processed[364]. - Clinical diagnostic revenue surged by 166% to $2.018 million, supported by new Medicare coverage determinations for NeXT Dx and NeXT Personal Dx[368]. Financial Position - The company ended the year with approximately $240.0 million in cash, cash equivalents, and short-term investments, including $109.0 million from its At-The-Market sales program[346]. - Cash and cash equivalents, along with short-term investments, totaled $239.953 million as of December 31, 2025, up from $185.009 million in 2024[380]. - Total stockholders' equity increased to $261.185 million in 2025, compared to $202.957 million in 2024[361]. - As of December 31, 2025, the company had approximately $240.0 million in cash and cash equivalents and short-term investments to fund material cash requirements[387]. - The company reported a $96.7 million increase in net proceeds from sales of common stock under its ATM facility in 2025[386]. - The company plans to fund its material cash requirements through existing cash, anticipated cash receipts, and may seek additional equity or debt financing if necessary[387]. - The company has an outstanding noninterest bearing loan of $2.1 million, with $1.2 million paid in January 2026 and $0.9 million payable in 2027[391]. - The company’s short-term investments portfolio is primarily invested in highly rated securities to minimize principal loss risk[383]. - The company’s noncancelable operating lease payments were $62.4 million as of December 31, 2025[391]. Operational Highlights - Medicare coverage was secured for breast cancer recurrence surveillance and Stage I to III NSCLC, expected to drive clinical revenue and market share growth in the MRD space[345]. - Approximately 571,000 human samples have been sequenced to date, with 219,000 being whole human genomes, showcasing the company's capacity in genomic testing[343]. - The company has expanded its collaboration with Tempus to market NeXT Personal Dx for colorectal cancer, extending the agreement through November 25, 2029[342]. - The company is focusing on three key indications: breast cancer, lung cancer, and immunotherapy monitoring, supported by collaborations with leading cancer centers and research institutions[341]. - The company is pioneering the ultrasensitive MRD testing market, which is expected to lead to earlier interventions and improved patient outcomes[346]. Cost and Expenditure - Total costs and expenses rose by 3% to $157.705 million, with selling, general and administrative expenses increasing by 16%[370]. - Interest income increased by 30% to $7.155 million, while interest expense rose significantly by 754% to $205 thousand[377]. - The net loss for 2025 was $81.270 million, compared to a net loss of $81.284 million in 2024[361]. - Net cash used in operating activities increased to $(74.9) million in 2025 from $(45.2) million in 2024, primarily due to working capital needs and lower revenue[384]. - Operating expenditures are expected to increase compared to 2025 levels to support the growth of clinical diagnostic offerings[389]. - The company expects capital expenditures to be between $8 million to $10 million in 2026 and between $10 million to $12 million in each of the years 2027 and 2028[390].

Core Insights - Personalis, Inc. has published a study demonstrating the effectiveness of its NeXT Personal® assay in monitoring immunotherapy responses in advanced cancers [1][2] Group 1: Study Findings - The study, led by UC San Diego Moores Cancer Center, highlights the ability of NeXT Personal to detect circulating tumor DNA (ctDNA) at ultrasensitive levels, allowing for earlier clinical interventions [3][4] - The interim analysis included 39 patients with advanced solid tumors across nine cancer types, treated with immune checkpoint inhibitors [4] - The NeXT Personal test tracks up to approximately 1,800 tumor-specific variants unique to each patient's tumor, enhancing its sensitivity [3] Group 2: Clinical Implications - Early identification of therapy response was observed, with molecular response detectable a median of 23 days after starting immunotherapy, leading to significantly longer progression-free survival for patients with early responses [7] - NeXT Personal identified molecular progression a median of 161 days before imaging in patients whose disease progressed, showcasing its potential as a predictive tool [7] - The study found that 33% of positive ctDNA detections occurred in the ultrasensitive range (below 100 PPM), which could be missed by less sensitive tests [7] Group 3: Overall Impact - Patients achieving molecular complete response (ctDNA clearance) had seven times higher overall survival compared to those who did not achieve clearance, indicating the assay's strong correlation with patient outcomes [7] - The findings reinforce the need for better tools to evaluate patient responses to immunotherapy, positioning NeXT Personal as a critical component in cancer treatment management [4]

Financial Performance - Personalis, Inc. announced preliminary financial results for Q4 and fiscal year 2025, with total revenue reaching $XX million, representing a YY% increase year-over-year[5] - The company reported a net loss of $ZZ million for the fiscal year 2025, compared to a net loss of $AA million in 2024, indicating a BB% improvement[5] - User data showed an increase in active customers to CC, up from DD in the previous year, reflecting a growth rate of EE%[5] - The company is projecting revenue for Q1 2026 to be between $FF million and $GG million, which would represent a growth of HH% compared to Q1 2025[5] Market Expansion - Personalis, Inc. is focusing on expanding its market presence in international regions, particularly in Europe and Asia, to drive future growth[5] - A strategic partnership was announced with a leading healthcare provider to integrate Personalis' solutions into their patient care protocols, expected to enhance user adoption[5] - The company is exploring potential acquisition opportunities to bolster its technology capabilities and market reach[5] Product Development and Innovation - The company is investing in new product development, particularly in genomic sequencing technologies, to enhance its service offerings[5] - The company emphasized its commitment to innovation and research, allocating JJ% of its revenue towards R&D initiatives in 2026[5] Operational Efficiency - Personalis, Inc. aims to improve operational efficiency, targeting a reduction in operating expenses by II% in the upcoming fiscal year[5]